Quick Answer
Black Diamond Therapeutics, Inc. reported Cash and Equivalents of $20.99 million for fiscal year 2025.
Black Diamond Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $20.99M | -42.4% |
| 2024 | $36.44M | -35.2% |
| 2023 | $56.22M | +63.8% |
| 2022 | $34.31M | -47.8% |
| 2021 | $65.80M | +90.1% |
| 2020 | $34.60M | -77.6% |
| 2019 | $154.67M | +199.4% |
| 2018 | $51.66M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.86M | +31.8% | +2.9% |
| June 30, 2025 | $29.99M | -8.6% | -69.5% |
| March 31, 2025 | $98.42M | +287.2% | +170.1% |
| December 31, 2024 | $36.44M | -35.2% | +55.5% |
| September 30, 2024 | $23.43M | -59.6% | -28.6% |
| June 30, 2024 | $32.81M | -21.7% | +29.1% |
| March 31, 2024 | $25.42M | -35.1% | -54.8% |
| December 31, 2023 | $56.22M | +63.8% | -3.0% |
- Black Diamond Therapeutics, Inc. showed a decrease of -42.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Black Diamond Therapeutics, Inc.’s cash and equivalents has declined by 59.4% (from $51.66 million to $20.99 million).
- The most recent figure is from Black Diamond Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: